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Abstract 
Human papillomavirus (HPV) 52 is commonly found in Asian cervical cancers, but rare 
elsewhere. Analysis of 611 isolates collected worldwide revealed geographical variation in 
lineage distribution, with lineage B predominating in Asia (89.0% vs. 0-5.5%, Pcorrected<0.001); 
whereas Africa, Americas and Europe were predominated by lineage A. Lineage B conferred 
a higher risk for cervical intraepithelial neoplasia 3 and invasive cancers than lineage A (OR 
[95%CI] = 5.46 [2.28-13.07]). The reported high disease attribution of HPV52 in Asia is likely 
due to the high prevalence of lineage B. We propose to name lineage B as “Asian” lineage to 
signify this feature.  
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Introduction 
Overall, human papillomavirus (HPV) 52 ranks the sixth or seventh among cervical 
cancers worldwide [1, 2].  However, studies from East Asia have reported a much higher 
ranking of HPV52. For instance, HPV52 was the third in squamous cell carcinoma, and the 
second among cervical intraepithelial neoplasia (CIN) 2 and CIN3 in Hong Kong [3]. 
Furthermore, HPV52 was the most common type in cervical cancers from Shanghai [4], and 
being the second in Taiwan [5] and Japan [6]. While the geographical predilection in disease 
attribution is obvious, its underlying reason remains obscure. We investigated the 
geographical distribution and risk association of HPV52 variant lineages using a large series 
of samples collected worldwide to improve our knowledge on this non-vaccine-targeted 
HPV type.  
 
Material and Methods 
Study Samples 
Cervical and vaginal samples from women or anal samples from men tested positive 
for HPV52 were transferred to a central laboratory for sequence analysis. DNA quality was 
assessed by amplifying a 932-bp fragment of LCR, and HPV type was ascertained by 
demonstrating a nucleotide sequence similarity of >90% compared with HPV52 prototype 
(GenBank accession no. X74481). The local institutional research ethics committee approved 
the collection of samples. Samples used in this study were sent without identifying patient 
information. 
 
Nucleotide Sequencing 
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The E6, E7, L1 and LCR were amplified by long-fragment or short-fragment 
polymerase chain reaction (PCR). Long-fragment PCR was applied to good-quality samples 
using primers 5'-ATG TCC ATT GAG TCA GGT CC-3' and 5'-TGC ATT TTC ATC CTC GTC C-3', 
and then a second PCR using inner primers 5'-GGT CCT GAC ATT CCA TTA CC-3' and 5'-CCT 
CTA CTT CAA ACC AGC CT-3' when necessary. Short-fragment PCR was used when the long-
fragment approach failed. E6, E7, L1 and LCR were amplified separately using primer pairs 
E6E7 (5'-TGC ACT ACA CGA CCG GTT A-3' and 5'-CAT CCT CGT CCT CTG AAA TG-3'), L1A (5'-
ATG TCC ATT GAG TCA GGT CC-3' and 5'-GCA CAG GGT CAC CTA AGG TA-3'), L1B (5'-AGG 
ATG GGG ACA TGG TAG AT-3' and 5'-CAC AGA CAA TTA CCC AAC AGA C-3') and LCR (5'-GTC 
TGC ATC TTT GGA GGA CA-3' and 5'-TGC GTT AGC TAC ACT GTG TTC-3'). When necessary, a 
second-round of PCR using inner primer pairs E6E7 (5'-TTA CCG TAC CCA CAA CCA CT-3' and 
5'-CCT CTA CTT CAA ACC AGC CT-3'), L1A (5'-GGT CCT GAC ATT CCA TTA CC-3' and 5'-GGG 
CAC ATC ACT TTT ACT AGC-3'), L1B (5'-ACA GGA TTT GGT TGC ATG G-3' and 5'-TTC TTT GTG 
GAG GTA CGT GG-3') and LCR (5'-TTT GTT ACA GGC AGG GCT AC-3' and 5'-CGT TTT CGG TTA 
CAC CCT A-3') was performed. The PCR products were sequenced from both directions, and 
analyzed with SeqScape software (version 2.5, Applied Biosystems). Mutations that 
occurred only once were confirmed by repeat sequencing from the original sample. 
 
Phylogenetic Tree Construction 
The concatenated nucleotide sequences assembled from the E6, E7, L1 and LCR 
regions were used for phylogenetic tree construction. Representative variants of each 
lineage and sub-lineage identified from a previous study were incorporated for lineage 
identification [7]. Maximum-likelihood trees were constructed using the Subtree-Pruning-
Regrafting (SPR) search approach by the Molecular Evolutionary Genetic Analysis (MEGA) 
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Software program (version 5.10, http://www.megasoftware.net/) [8]. The data were 
bootstrap resampled 1,000 times for tree topology evaluation.  
 
Geographical Distribution of Variant Lineages 
The detection rate of each variant lineage was compared among regions by Chi-
squared test or Fisher’s exact test as appropriate with correction for multiple comparisons 
using the Bonferroni method. Epi Info (version 7.0.8.3, Centers for Disease Control and 
Prevention, Atlanta) was used to calculate the P values. Multivariate analyses were 
performed to investigate the association between each lineage and disease, controlling for 
age. Subjects with normal cervical cytology were used as controls, whereas subjects with 
histologically confirmed CIN3 or invasive cervical cancer were categorized as cases. Two-
tailed P values of < .05 were regarded as significant. The software package for statistical 
analysis (SPSS version 20, IBM) was used for multivariate analysis. 
 
Results 
Altogether, 611 specimens collected from 14 sites had DNA quality sufficient for 
sequencing (Supplementary Table S1). Of these, 73.2% were from Asia, 15.5% from Europe, 
9% from Americas and 2.3% from Africa. Most samples were from women with normal 
cervical cytology (31.3%) and high-grade lesions (30.1%) including high-grade squamous 
intraepithelial lesions (HGSIL), CIN2 and CIN3. Altogether, 25 (4.1%) cervical samples had no 
associated cytological or histological information, and another 2.3% were vaginal samples. 
The mean age of study subjects was 41.1 years (standard deviation: 14.0, range: 13-88).  
 
Lineage Identification 
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 The concatenated E6-E7-L1-LCR sequences derived from referent strains of each 
sublineage of HPV52 formed distinct branches in the phylogenetic tree, suggesting that 
these concatenated sequences comprising 40.6% (3226 nt) of the whole HPV52 genome can 
be used for lineage identification (Supplementary Figure S1). The tree topology of E6-E7-L1-
LCR sequences derived from the 324 unique strains collected in this study revealed three 
closely related but distinct branches representing lineages A, B and C; and one distantly 
related branch representing lineage D. 
The phylogenetic trees constructed from L1 or LCR sequences alone showed a 
topology similar to that of E6-E7-L1-LCR, and were able to identify variants up to the lineage 
level, but could not differentiate sublineages. Signature sequences within the L1 and LCR 
regions useful for lineage/sublineage identification are shown in Supplementary Figure S2. 
The phylogenetic trees constructed from E6 or E7 sequences alone showed a topology quite 
different from that of E6-E7-L1-LCR, and were not useful for lineage identification. 
 
Geographical Distribution of Variant Lineages 
 Variation in distribution of HPV52 lineages according to geographical location was 
observed (Figure 1).  Lineage B was significantly more prevalent in Asia compared to 
elsewhere (89.0% in Asia vs. 0-5.5% elsewhere, Pcorrected < 0.001 for each comparison). In 
contrast, Africa, the Americas and Europe were all predominated by lineage A that 
accounted for 78.6-96.8% of the isolates compared to 5.5% in Asia (Pcorrected < 0.001 for each 
comparison). Lineage C was uncommon across all regions (0% to 9.1%) and without 
significant variation. Lineage D was rarely detected in the Americas, Asia and Europe (0-
1.8%); but was found in 3 of 14 samples from Africa giving a wide 95% confidence interval 
(CI) of 0-42.9%. 
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The majority (93.7%) of lineage A variants belonged to sublineage A1, which was 
consistently observed across regions.  All lineage B variants identified in this study were 
sublineage B2, and all lineage C variants belonged to sublineage C2. 
 
Risk Association of Variant Lineages 
 The distribution of variant lineages and sublineages according to cervical pathology 
status is shown in Table 1. Multivariate analyses adjusting for age were performed to 
compare subjects with normal cervical cytology as controls against subjects with 
histologically confirmed CIN3 or invasive cervical cancer as cases. Lineage B was found to 
associate with a significantly higher risk than lineage A (age-adjusted OR [95% CI] = 5.46 
[2.28-13.07]). Lineage C was also associated with a significantly higher risk than lineage A 
(age-adjusted OR [95% CI] = 7.78 [2.26-26.75]. Lineage B appeared to associate with a higher 
risk than lineage C, but the difference was not statistically significant (age-adjusted OR [95% 
CI] = 1.42 [0.56-3.56]. The number of isolates belonging to lineage D was too few for analysis.  
 
Discussion 
 Intratypic variants of HPV are divided into lineages based on the topology of 
phylogenetic tree and a difference of >1% in their full genome sequences [7]. Such 
classification of variants is important not only for understanding the evolution of HPV, but 
also because it carries biological implications. HPV52 has evolved into four lineages, for 
which the geographical distribution and risk implication have been uncertain [7], but are 
addressed in this study. The main strengths of our study are the large number of samples 
collected around the world, and the ability to restrict the risk association analysis to cases 
with histologically confirmed diagnoses. Nevertheless, this study had limitations in not being 
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able to account for coinfection with other high-risk HPV types, the number of samples 
available from some regions such as Africa was relatively small, and some samples did not 
have associated cytological/histological diagnoses. 
 To date, only a few studies have investigated the distribution of HPV52 lineages. 
Chang et al. found that among Taiwanese women, lineage B was the most prevalent (88.2%), 
followed by lineage C (11.1%), while lineage A was rare (0.7%) [9]. In contrast, lineage A was 
the most frequently found in Canada, especially among Caucasian [10, 11]. Another study 
examined samples collected from Japan, the Philippines and Vietnam, and reported that 
lineage B was the most prevalent followed by lineage A [12]. However, that study used E6 
and E7 sequences to identify variant lineages, which is suboptimal for such purposes.  
 Our study assessed the distribution of HPV52 variants based on 611 samples 
collected from 14 cities across 4 continents providing the largest data set for assessing 
geographical distribution from a worldwide perspective. The most remarkable finding was 
the dominance of lineage B, but rare occurrence of lineage A, in Asia. The exact opposite 
was true in non-Asian regions. Therefore, we propose to name lineage B of HPV52 as “Asian 
(As)”, and lineage A as “non-Asia (nAs)” to signify their characteristic geographical 
distribution. 
 Studies on risk association of HPV52 variants are limited and inconclusive. Ding et al. 
examined the E6 and E7 sequences of 121 samples from Zhejiang, Eastern China, but could 
not identify any variant with increased or decreased oncogenic risk [13]. Sun et al. analyzed 
the L1, E6, E7 and LCR sequences of 72 samples from Shengjing, Northeast China [14]. In 
that study, the variants were not grouped according to the lineage classification system 
proposed by Chen et al. [7], and no significant risk association was observed. Ishizaki et al. 
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studied 109 samples from Japan, the Philippines and Vietnam. Again, no significant 
association between E6 and E7 sequence variation and abnormal cytology was found [12].  
 Although examination of E6 and E7 sequence variation did not reveal any significant 
differences in risk association among HPV52 variants, some interesting findings were 
observed when lineage classification was taken into account. Chang et al. used LCR-E6-E7 
sequences to identify the lineage of 280 samples from Taiwan, and reported a higher risk of 
CIN for lineage C compared to lineage B variants [9]. Unfortunately, lineage A was found in 
two samples only and therefore precluded from risk association comparison.  Two studies 
on risk association of HPV52 variants were available from Canada.  Aho et al. showed that 
non-prototypic LCR variant was an independent predictor for viral persistence [11]. The 
observations from Formentin et al. suggested that variant MTL-52-LCR-21 that belongs to 
sublineage A1 and variant MTL-52-LCR-02 that belongs to sublineage A2 conferred a higher 
risk. However, most of the isolates available in these Canadian studies were of lineage A, 
precluding the comparison among different lineages. Schiffman et al. examined HPV52 
samples derived from the Guanacaste Cohort Study, and observed that all CIN2+ cases were 
infected with lineages A/B/C suggesting a lower risk for lineage D [15]. However, the 
observation was highly unstable and not statistically significant. 
 The current study has generated the most comprehensive data for analyzing risk 
association of HPV52 variant lineages with cervical disease. Based on our observations, we 
propose to classify lineage A as a “low-risk” lineage of HPV52, whereas lineages B as a “high-
risk” lineage. Lineage C is probably “high-risk” as well. Lineage D is rare and cannot be 
assigned to a risk category at this stage. Nevertheless, this risk classification should be 
further evaluated preferably with assessment on the transforming ability of these variants 
using in-vitro or in-vivo models. 
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 In conclusion, we found that classifying HPV52 variants into lineages carries 
epidemiological and pathological implications. Lineage B can be regarded as “Asian” and 
“high-risk” based on its geographical distribution and risk for cervical neoplasia. The 
reported higher disease attribution of HPV52 in Asia is likely to be a result of the higher 
prevalence of lineage B in that region. The unique epidemiological feature of HPV52 in Asia 
should be considered in the design and evaluation of diagnostic assays and vaccines 
intended for Asia.   
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Figure legends 
Figure 1. Distribution of HPV52 variant lineages and sublineages according to geographical 
regions. 
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Online supplementary materials 
Supplementary Figure S1. Phylogenetic trees showing HPV52 variant lineages and 
sublineages.  
Maximum-likelihood trees were constructed using the program MEGA 5 based on 
concatenated E6-E7-L1-LCR nucleotide sequences of 324 unique HPV52 strains collected in 
this study and published referent strains of each sublineage (A1: X74481, A2: HQ537739, B1: 
HQ537740, B2: HQ537743, C1: HQ537744, C2: HQ537746, D: HQ537748). The unrooted tree 
showing sublineage clustering of each sequence. Samples examined in this study are labeled 
with different colours and symbols according to the region and country, respectively. Solid 
black triangles denote sublineage referent strains. The box in right lower quadrant shows 
the rooted tree displaying overall topology. Bootstrap values of key nodes generated by 
1,000 resampling are shown. The length of the scale bar represents 0.003 substitutions per 
nucleotide position. HPV67 prototype sequence (GenBank accession no. NC_004710) was 
set as the outgroup and represented by a grey broken line.  
 
Supplementary Figure S2. L1 and LCR sequence signatures for HPV52 lineage/sublineage 
identification. 
Vertical numbers represent nucleotide positions according to the HPV52 prototype 
(GenBank accession no. X74481). Sites with no changes are marked with dashes. C6483A, 
A6711G, C6983G are nonsynonymous substitutions, others are synonymous. Y = C or T, S = 
G or C, M = A or C, del = deletion, ins = insertion. a Deletion of TG at nucleotide position 
7287 and 7288. b Deletion in 1 sample. c Insertion of GT between nucleotide positions 7287 
and 7288. d T to G substitution in 2 samples, deletion in 7 samples. GenBank accession no. 
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for E6 variants: KJ675743 - KJ675789; E7 variants: KJ675790 - KJ675805; LCR variants: 
KJ675806 - KJ675962; L1 variants: KJ675963 - KJ676095. 
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Table 1. Distribution of HPV52 variant lineages according to cervical pathology status 
Lineage / sublineage 
(N) 
No. (%)  of subjects1 
Normal cervical cytology 
(N=191) 
Cervical intraepithelial neoplasia 3 
(N=111) 
Invasive cervical cancer 
(N=41) 
A (36) 30 (15.7%) 4 (3.6%) 2 (4.9%) 
 A1 (34)  28 (14.6%)  4 (3.6%)  2 (4.9%) 
 A2 (2)  2 (1.0%) 0  0 
 
B (289) 155 (81.2%) 98 (88.3%) 36 (87.8%) 
 B1 (0)  0  0  0 
 B2 (289)  155 (81.2%)  98 (88.3%)  36 (87.8%) 
 
C (14) 5 (2.6%) 6 (5.4%) 3 (7.3%) 
 C1 (0)  0  0  0 
 C2 (14)  5 (2.6%)  6 (5.4%)  3 (7.3%) 
 
D (4) 1 (0.5%) 3 (2.7%) 0 
 
1 All cervical intraepithelial neoplasia 3 and invasive cervical cancer cases were diagnosed by histology. 
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Supplementary Figure S2. L1 and LCR sequence signatures for HPV52 lineage/sublineage identification 
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Prototype  C A T G C C T C G T A G C T T G  G G T G G G T T T G C C A T T C T G A G C A T C 
A                   
   
  
            
       
A1 163 - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - Y - - - - - - - - - - 
A2 11 - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - Y - - - - - - - - - - 
B                   
   
  
            
       
B1 0                  
   
  
            
       
B2 402 - - - A - - - - - G - - - - - -  S - dela T - - - - - - - - G C - - C - A M - - - 
C                   
   
  
            
       
C1 0                  
   
  
            
       
C2 26 - G - A T - - - A - - - - - - -  - - - - - - - C C A - - - G C T C C G A A Ab - - 
D 9 A - C A - A C A - - G A G C C A  T C Insc - T G - - - T G C G - - Sd C - A G G C T 
 
Vertical numbers represent nucleotide positions according to the HPV52 prototype (GenBank accession no. X74481). Sites with no changes are 
marked with dashes. C6483A, A6711G, C6983G are nonsynonymous substitutions, others are synonymous. Y = C or T, S = G or C, M = A or C, 
del = deletion, ins = insertion. 
a Deletion of TG at nucleotide position 7287 and 7288. 
b Deletion in 1 sample. 
c Insertion of GT between nucleotide positions 7287 and 7288. 
d T to G substitution in 2 samples, deletion in 7 samples. 
Supplementary Table S1. Geographical source and pathological status of specimens 
    No. of specimens according to cervical pathology status 
Region, 
country or city 
All lesion grades Normal ASCUS Low-grade High-grade Carcinoma Unknown 
Africa 14 0 0 0 0 0 14 
Zimbabwe 14 0 0 0 0 0 14 
        Americas 55 1 0 1 2 1 9 
Argentina 9 0 0 0 0 0 9 
Canada 1 0 0 0 1 0 0 
Mexico 4 1 0 1 1 1 0 
United States 41a 0 0 0 0 0 0b 
        Asia 447 168 5 69 162 40 3 
Hong Kong 321 127 3 36 128 27 0 
Japan 21 0 0 11 9 1 0 
Korea 91 40 2 20 23 5 1 
Shanghai 2 0 0 0 0 0 2 
Taiwan 10 0 0 2 2 6 0 
Thailand 2 1 0 0 0 1 0 
        Europe 95 22 0 40 20 0 13 
Croatia 40 0 0 21 19 0 0 
Italy 14 4 0 4 1 0 5 
United Kingdom 41 18 0 15 0 0 8 
        Total 611 191 5 110 184 41 39b 
 
ASCUS, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; 
High-grade includes high-grade squamous intraepithelial lesions (HGSIL), CIN2 and CIN3; Low-grade 
includes low-grade squamous intraepithelial lesions (LGSIL) and CIN1. 
a anal swab samples. 
b not include 41 anal samples. 
